ReviewPharmaceutics2023
Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis.
Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis.Acta dermato-venereologica · 2026Trial
- Atopic dermatitis.Nature reviews. Disease primers · 2026Review
- Extracellular vesicles fromFrontiers in immunology · 2026Article
- From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies.International journal of molecular sciences · 2025Review
- IL-31/33 Axis in Atopic Dermatitis.International journal of molecular sciences · 2025Review
- Review
- Advancing Therapeutic Strategies in Atopic Dermatitis: Emerging Targets and Personalized Approaches.Biomolecules · 2025Review
- Type 2 Inflammation and Its Role in Dermatologic Diseases.International journal of dermatology · 2025Review
- The Neuroimmune Axis in Atopic Dermatitis: From Pathogenic Mechanisms to Targeted Neuroimmunotherapy.Journal of inflammation research · 2025Review
- Advances of bispecific antibodies using/application in dermatology: a review.Frontiers in allergy · 2025Review
- Mast cell-neuron axis as a core mechanism in chronic pruritus of atopic dermatitis: from mechanistic insights to therapeutic targets.Frontiers in immunology · 2025Review
- Beyond the blockade: unmet needs in systemic targeted atopic dermatitis therapy.Frontiers in immunology · 2025Review
- Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment Decisions.Immune network · 2024Review
- Potential Aspects of the Use of Cytokines in Atopic Dermatitis.Biomedicines · 2024Review
- Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies.Current issues in molecular biology · 2024Review
- The role of nemolizumab in the treatment of atopic dermatitis for the adult population.Immunotherapy · 2024Review
- The IL-33/IL-31 Axis in Allergic and Immune-Mediated Diseases.International journal of molecular sciences · 2023Article
- Novel Therapeutic Targets for the Treatment of Atopic Dermatitis.Biomedicines · 2023Review
- Basophils in pruritic skin diseases.Frontiers in immunology · 2023Review
- A review of catechins and their use in atopic dermatitis.Itch (Philadelphia, Pa.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD), a pruritic, inflammatory chronic disease with multifactorial pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not only the immunologic dysfunction and microbiome dysbiosis but also the recovery of the damaged skin barrier. The current review focuses on the interleukin 31 (IL-31) pathway and AD and offers an overview of the current clinical studies with monoclonal antibodies blocking this cascade. Pruritus, the key symptom of AD, has substantial participation of the IL-31 complex and activation of relevant signaling pathways. Epidermal keratinocytes, inflammatory cells, and cutaneous peripheral nerves express the interleukin-31 receptor α-chain (IL-31RA), upregulated by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.